By Carol Lynn Curchoe, PhD, CLD, HCLD 

Published February 2025  •  Regulatory Affairs  •  IVF & Tissue Banking Compliance

Let’s be honest: the regulatory environment governing tissue banks and gamete storage facilities has never been more fractured, more demanding, or more consequential than it is right now. Between expanding state-level legislation, evolving FDA oversight, and increasingly nuanced international frameworks, the compliance landscape that fertility clinics and sperm banks operate in today looks almost nothing like it did even five years ago.

For those of us who have spent careers in this space, the sheer volume of requirements — and the way they layer, contradict, and occasionally harmonize across jurisdictions — is something that keeps lab directors and compliance officers up at night. If you’re operating a tissue bank that handles donor semen for significant intimate partner (SIP) use, known donation, or anonymous donation, this piece is for you. We’ll take a deep dive into the federal baseline, walk through the most demanding state requirements (with particular attention to Colorado, which has become a genuinely distinct regulatory environment), and touch on the international frameworks you’re likely navigating if you distribute or receive specimens across borders.

This isn’t an academic overview. This is operational guidance drawn from real compliance work.

The Federal Foundation: FDA and CLIA

Before we get into state-specific complexity, it’s worth reestablishing the federal baseline, because everything else layers on top of it. Tissue banks that collect, process, store, or distribute semen must be registered with the FDA as a human cells, tissues, and cellular and tissue-based products (HCT/P) establishment under 21 CFR Part 1271. This means donor screening, infectious disease testing, and record-keeping must conform to FDA requirements — not as a formality, but as an ongoing operational reality that FDA inspectors will verify.

FDA inspections aren’t particularly frequent for most tissue banks, but when they happen, they’re thorough. If you receive a Form 483 with observations, the clock starts ticking on your corrective action response. Timely, substantive responses matter — both for the immediate issue and for how the agency views your facility going forward. An internal corrective action log that’s reviewed regularly and linked to your quality management system isn’t optional; it’s what separates facilities that sail through re-inspections from those that don’t.

On the CLIA side, laboratories performing clinical testing in connection with tissue banking operations must maintain CLIA certification, and many facilities choose to work with an accreditation agency that performs routine inspections and reports directly to the state CLIA authority. Accreditation standards tend to be somewhat more prescriptive than the CLIA baseline, and the overlap with FDA requirements on things like specimen handling and documentation creates a meaningful compliance burden for labs that aren’t well-organized.

The takeaway on the federal level: get your quality assurance records, staff training logs, and SOPs into shape and keep them there. These aren’t inspection-time documents. They’re living operational records.

Colorado: The Most Demanding State Regulatory Framework in the Country

Let’s spend real time here, because Colorado deserves it. In the last several years, Colorado has enacted some of the most detailed, operationally specific requirements for gamete agencies, banks, and fertility clinics of any state in the nation. Whether you’re a Colorado-based entity or an out-of-state organization that ships to Colorado recipients or matches with Colorado-located medical providers, these rules apply to you in ways that are not always intuitive.

The Age Requirement and Its Effective Date

Effective January 1, 2025, Colorado requires that gamete donors must be at least 21 years of age at the time of consent. This isn’t simply a policy preference you can note and move on from — your procedure manual must explicitly describe the steps your entity takes to limit donations to donors who meet this threshold and to assess and monitor adherence to the age limit. For facilities that have historically worked with donors in the 18–20 age range, this represents a meaningful operational change that needs to flow through your SOPs, your intake screening process, and your staff training.

Donor and Recipient Education: More Than a Checkbox

Colorado is explicit that donor and recipient education is an obligation. Your SOP must describe, in detail:

• How educational materials are distributed to and discussed with donors and potential donors prior to gamete collection.
• How educational materials are distributed to gamete or embryo recipients prior to matching or the provision of gametes or embryos.

This isn’t about having a pamphlet on file. Regulators reviewing your SOPs during the application or inspection process will look for documented processes, not just the existence of materials. Who distributes them? When in the process? How is completion documented? These are the questions your procedures need to answer.

The 25-Family Limit: Good Faith Is Required, but Good Faith Has Teeth

Colorado caps the number of families that may be established using a single donor’s gametes at 25. This is not a soft guideline. Your procedures must describe:

• The methods used to ensure that gametes from a donor are not matched or provided to additional families once 25 or more families have been established.
• How potential donors are informed that they may request a lower family limit.
• How compliance with requests for lower family limits is verified and maintained.

The state recognizes the practical challenge of tracking live births across distributed recipient populations and has built in a good-faith standard, but the regulation specifies what good faith actually means:

• Sufficient record-keeping.
• Requiring recipients, as a condition of receiving donor gametes, to provide information on live births, and requesting this information from recipients.
• Using industry best practices or multiple commercially reasonable methods to account for the number or percentage of live births, whether reported or not.

The limit also comes with specific exclusions that must be tracked separately:

• Children conceived when the donor was known to the recipient parent(s) at the time of donation.
• Children conceived by the donor as a parent.
• Embryos transferred from one family to another.

Identity Disclosure: A Non-Negotiable in Colorado

This is where Colorado most sharply diverges from the practices that have been standard in anonymous donation programs for decades. Colorado requires that donors agree to identity disclosure — and for entities operating within the state, this means you may not match or collect gametes from a donor who does not agree to this disclosure.

For out-of-state entities, the requirement is framed differently but is equally binding: you must not match or provide gametes to a recipient parent or medical provider located in Colorado from a donor who has not agreed to identity disclosure. If you operate a national or international sperm bank and you distribute to Colorado, this means every donor whose samples might be shipped to Colorado recipients must have an identity disclosure consent on file.

The procedural requirements around disclosure are detailed. Your SOP must address:

• How donors are provided information about disclosing identifying information, including full name, date of birth, permanent and current address, and medical history.
• How notarized or witnessed signed consent agreeing to identity disclosure is obtained.
• How consent to medical history disclosure is separately obtained.
• When in the donation process the declaration of disclosure is signed.
• The length of time the declaration is valid and whether it must be re-signed for each cycle.

Donor-Conceived Person (DCP) Rights and Information Access

Colorado’s framework is explicitly oriented toward the interests of donor-conceived persons. When a DCP reaches age 18, they have the right to request identifying information about their donor. Your procedure must address:

• What donor information is shared with a DCP and through what mechanism (e.g., secure portal, encrypted email, physical copies).
• How identity between the DCP and the associated donor record is verified, using methods that do not impede or prohibit communication. Verification may rely only on government-issued ID and the name and date of birth of the birth parent who received the donated gametes or embryos — entities may request but not require additional documentation.
• The defined timeline within which such requests must be fulfilled.

Record Retention: In Perpetuity, Not a Figure of Speech

Colorado’s record retention requirement is as close to absolute as regulations get. Identifying information and medical history for donors matched with or providing gametes to unknown recipients, family count data and the efforts to obtain it, and gamete screening and testing records must all be permanently maintained.

This has real implications for how your document management systems are structured. Electronic records systems that archive after a certain period, platforms that sunset older data, or paper records in facilities without long-term storage plans are all potential compliance failures waiting to happen. The records must also remain traceable to the associated gametes — a point that’s easy to underestimate until you’re trying to reconstruct a chain of custody years or decades later.

Traceability of Gamete Source Entities and Inter-Entity Transfers

For entities receiving gametes or embryos from another entity on or after July 1, 2024, Colorado requires permanent maintenance of the providing entity’s name, address, telephone number, and email address. For fertility clinics that collect gametes from donors matched by a separate gamete agency on or after that same date, the same information must be maintained for the matching agency.

This inter-entity traceability obligation extends to disclosure rights. When a DCP or parent/guardian requests information about the source entity for gametes received from another entity after July 1, 2023, your procedure must describe how you receive the request, verify the requestor’s connection to the gametes, share the required contact information, and fulfill the request within a defined timeline.

All of this contact information must also include your Colorado license number, and it must remain traceable to the specific gametes it relates to — not just stored somewhere in your records system.

Ovum Donor Cycle Limits

For entities that handle egg donors in addition to sperm donors, Colorado caps the total number of retrieval cycles at six in a donor’s lifetime. This requires active monitoring, not passive record review — your procedure must describe how you assess and track adherence to this limit across the donor’s entire donation history, including at other facilities.

There is a narrow exception for prior donors who provide informed consent to undergo additional cycles for families who have already conceived children with that donor. But this exception requires its own documented procedure: how you assess and monitor it, and how you establish a connection between the recipient parent(s) and the donor in those circumstances.

SOP Accuracy, Training, and the Employee Verification Requirement

Colorado specifies not just what your SOPs must cover, but how your facility must manage them. Your procedures must describe:

• How you ensure SOPs accurately reflect actual practices.
• How employees are trained to procedures and how evidence of that training is maintained.
• How periodic reviews verify that policies and procedures continue to reflect actual practices.

Your training plan must specifically include:

• Identification of which policies and procedures each employee role must be trained on.
• A requirement to verify training is completed before staff perform steps independently.
• Training record templates with spaces for dates, and signatures from both the employee and a supervisor or senior staff member — wet signatures or e-verifiable signatures required.

Business Continuity: The Bankruptcy and Dissolution Plan

One of the requirements that catches organizations off guard is Colorado’s mandate that entities maintain a written plan for bankruptcy, dissolution, or insolvency. At minimum, this plan must identify the types of records that will be transferred to a receiving entity, the timeframe for providing records to that entity, and the timeframe for providing required information to the state Department of Health. If your organization doesn’t have this plan drafted, it’s a gap that needs to be closed before your next compliance review.

Other State Regulatory Frameworks

Colorado may be the most demanding, but it isn’t the only state with meaningful compliance requirements. Here’s a working overview of what you’re dealing with in other key jurisdictions.

California

California requires annual registration with associated fees, and while the chance of a formal inspection is lower than in some other states, the registration process itself is substantive. All SOPs and consent forms are reviewed during the application process, which means your documents need to be in shape before you submit, not after. For facilities that operate in multiple states, California’s front-end SOP review is actually a useful forcing function for getting your procedures in order.

New York

New York has no registration fees but compensates with a robust oversight structure. SOPs are reviewed during the application process, and the frequency of inspections is determined by the nature and volume of the facility’s activities — which means high-volume operations should expect more scrutiny.

The most distinctive New York requirement is mandatory participation in an annual Tissue Bank Advisory Meeting. Your Medical Advisory Committee must consist of at least five members with expertise in human fertility, infectious disease, or related fields — and this committee composition needs to be documented and defensible, not just nominal.

Illinois, Delaware, and Oregon

These three states require annual registration with no fees and conduct no routine inspections. SOPs are not reviewed during registration. For multi-state operators, these are relatively low-friction jurisdictions — but that doesn’t mean you can neglect the underlying operational quality. Federal requirements and accreditation standards still apply fully.

Maryland

Maryland requires a one-time registration with no fees and no routine inspections. SOPs are not reviewed during registration. The administrative burden is minimal, but again, this is not a jurisdiction where you can cut operational corners — it simply means the state isn’t looking over your shoulder in the same way others are.

International Regulatory Frameworks

Canada

Canadian compliance for tissue and donor semen banking centers on registration and adherence to Health Canada guidelines covering donor screening, infectious disease testing, and traceability. Canadian requirements around traceability and infectious disease testing have significant operational overlap with FDA requirements, but they are not identical — particularly around the specific testing panels and documentation standards. If you’re importing or exporting specimens to Canada, your records and labeling need to satisfy both frameworks simultaneously.

United Kingdom

The Human Fertilisation and Embryology Authority (HFEA) is one of the more rigorous international regulatory bodies a tissue bank is likely to interact with. UK registration requires ongoing use of HFEA-mandated MD and CD forms to document and track donor and patient consent, gamete testing, and storage compliance. The HFEA code of practice covers donor suitability assessment, records management, and reporting obligations in considerable detail.

For US-based facilities distributing to UK clinics, the HFEA inspection framework and documentation requirements represent a genuinely separate compliance track that must be maintained in parallel with FDA and state requirements. HFEA inspections can be thorough, and the expectation that all gamete tracking, consent, and testing documentation is complete and immediately accessible is not aspirational — it’s a baseline expectation.

Israel

Israel has among the most detailed genetic testing requirements of any country for imported donor sperm. Sperm from donors whose samples are imported into Israel must include an expanded panel for pathogenic genetic variants and chromosomal microarray analysis (CMA). Where a recipient woman is a carrier of a recessive disease, targeted gene sequencing or whole exome sequencing is required for the donor.

Donors must sign informed consent permitting preservation of a sample — either in Israel or abroad — specifically for future genetic testing if required. This consent must be obtained proactively, before samples are shipped.

The family limit in Israel is set at 12, significantly lower than Colorado’s 25-family cap. A single exception exists: the bank director may authorize provision to an additional recipient only when all ampoules allocated to a prior recipient have been used, all treatment cycles have concluded without a live birth, and no embryos remain for that recipient. Each of these conditions must be documentable.

The Operational Infrastructure That Makes This Work

You can know every regulation in this article and still fail a compliance review if your operational infrastructure isn’t designed to support sustained adherence. Here’s what that infrastructure looks like in practice.

Centralized Compliance Registry

A centralized registry of all required licenses, registrations, and renewal dates is not a nice-to-have. It’s how you avoid discovering mid-inspection that a state registration lapsed eight months ago. The registry should include the regulatory body, the license type, the renewal date, the responsible staff member, and links to the applicable regulations so that annual reviews can check for changes in requirements, not just renewal of the same obligations.

Roles and Responsibilities

Compliance across this many jurisdictions requires clearly delineated ownership. In practice, that typically means:

• A Regulatory Compliance Officer who monitors requirements, manages renewal timelines, and coordinates inspection readiness.
• A Laboratory Technical Supervisor who ensures daily operations conform to CLIA, FDA, accreditation, and state standards, and who owns quality assurance protocols.
• A State Licensing Specialist who maintains state-specific documentation and maintains working relationships with state health departments.
• An International Liaison who manages relationships and compliance with HFEA in the UK, Health Canada, and other international regulators.

The Annual Tissue Advisory Meeting

For facilities subject to New York’s requirements (and as a best practice more broadly), the annual Tissue Bank Advisory Meeting is a critical governance touchpoint. A well-structured meeting reviews:

• Licensure and registration status across all jurisdictions.
• Regulatory changes since the prior meeting.
• Document retention compliance across electronic systems.
• Corrective actions from prior inspection cycles and their effectiveness.
• Annual and new staff training completion.
• Incidents, occurrences, and any non-conformances.
• Review of consent forms, donor selection criteria, and social history forms.
• Key performance indicators from the annual quality assurance review.

The Bottom Line

The regulatory environment for tissue banks and fertility clinics handling donor semen is not getting simpler. Colorado’s framework in particular represents what appears to be a leading edge of state-level regulation — detailed, donor-conceived person-oriented, and operationally demanding in ways that require genuine procedural infrastructure rather than checkbox compliance.

For organizations distributing nationally or internationally, the challenge is managing multiple overlapping frameworks simultaneously — FDA and CLIA as a baseline, state-specific licensing in each jurisdiction where you operate or distribute, and international bodies like the HFEA and Health Canada where applicable. Each of these has its own inspection cadence, its own documentation standards, and its own gap between the minimum required and what actually constitutes defensible compliance.

The facilities that navigate this well share a few things in common: they treat their SOPs as living documents rather than static filings, they invest in compliance infrastructure before inspections rather than scrambling during them, and they recognize that regulatory requirements in reproductive medicine increasingly reflect the interests of the donor-conceived people whose lives begin from this work.

That’s not a burden to resent. It’s a responsibility to take seriously.

This article is intended for informational purposes for regulatory and compliance professionals in the reproductive medicine and tissue banking industries. It does not constitute legal advice. Regulatory requirements change frequently; always verify current requirements with the relevant regulatory authority or qualified legal counsel.